Cyclafem 1/35 and Central nervous system leukaemia - from FDA reports
There is no Central nervous system leukaemia reported by people who take Cyclafem 1/35 yet. This review analyzes which people have Central nervous system leukaemia with Cyclafem 1/35. It is created by eHealthMe based on reports from FDA, and is updated regularly.
What to expect?
You are not alone!
Personalized health information
On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>
On Aug, 19, 2017
No report is found.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Subscribe to the study: get notified of updates to the study.
Do you have Central nervous system leukaemia when taking Cyclafem 1/35?
- Check symptoms - is central nervous system leukaemia caused by a drug or a condition?
- Get alerts to symptoms - forecast your symptoms and get alerts
- Join related support groups - you are not alone, join a support group on ehealth.me
- Report the side effect - help people in need and in real time
- More tools...
Expand the study to include all drugs with the same ingredientsCentral nervous system leukaemia and drugs with ingredients of ethinyl estradiol; norethindrone.
Expand the study to include reports from both FDA and eHealthMeCentral nervous system leukaemia and Cyclafem 1/35 from FDA and eHealthMe reports
Cyclafem 1/35 has active ingredients of ethinyl estradiol; norethindrone. It is often used in birth control. (latest outcomes from Cyclafem 1/35 137 users)
Central Nervous System Leukaemia
Central nervous system leukaemia (cancer of central nervous system) has been reported by people with acute lymphocytic leukemia (all), chronic myeloid leukaemia, acute myeloid leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia recurrent (latest reports from 81 Central nervous system leukaemia patients).